Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
| Autor: | Ljiljana Vuckovic, Mirjana Miladinović, Aleksandra Klisic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pathology
medicine.medical_specialty her2 HER2 Antibody In situ hybridization amplification HercepTest lung Medicine skin and connective tissue diseases neoplasms ihc Lung adenocarcinoma biology business.industry General Medicine medicine.disease medicine.anatomical_structure biology.protein Immunohistochemistry Adenocarcinoma Antibody Anti her2 business |
| Zdroj: | Open Medicine, Vol 16, Iss 1, Pp 1503-1512 (2021) |
| ISSN: | 2391-5463 |
| Popis: | Background Discordant results exist about the role of human epidermal growth factor receptor 2 (HER2) overexpression and/or HER2 amplification in lung adenocarcinoma. We aimed to compare the performance of HercepTest and PATHWAY anti-HER2 (4B5) by correlating immunohistochemistry (IHC) results with silver in situ hybridization (SISH) in adenocarcinoma lung specimens. Methods A total of 148 surgically resected adenocarcinoma lung specimens were included. Results HER2 overexpression was found in 7.4% patients for HercepTest Dako and in 2.7% patients for 4B5 antibody. The overall coincidence between these two types of antibodies equals 93.9%. The incidence of HER2 amplification in lung adenocarcinoma was 17.6%, of which in 2.7% of the cases high-grade amplification was present. HER2 amplification was present in 90.9% of patients with overexpression of HER2, obtained by using HercepTest Dako and 75% patients using 4B5 antibody. A significant correlation between overexpression of HER2 receptors obtained by HercepTest Dako and 4B5 antibody and HER2 amplification was shown. Conclusion The research of the efficiency of targeted molecular therapies with an HER2 antibody may serve as a basis for the introduction of routine HER2 status determination in lung adenocarcinoma, dictating the need for the standardized protocol for HER2 status determination in such pathology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|